默克尔细胞癌的发病率、死亡率和生存率:基于人群研究的系统综述
该系统综述纳入24个国家52项基于人群的研究,总结默克尔细胞癌(MCC)的发病率、死亡率和生存率。MCC发病率随时间增加(高确定性),澳大利亚报告发病率最高(2.5/10万),男性发病率通常高于女性(高确定性)。生存率较低和/或死亡率较高与男性、诊断时分期较高、年龄较大和免疫抑制相关。
要点
- MCC发病率随时间增加,澳大利亚报告发病率最高(2.5/10万)。
- 男性MCC发病率通常高于女性(高确定性)。
- 男性、高分期、高龄和免疫抑制与较差的生存相关。
核心结论
- MCC发病率正在增加,且随着许多国家人口老龄化可能进一步上升。
- MCC预后较差,尤其是男性、免疫抑制、诊断时分期较高或年龄较大的患者。
研究设计与样本
- 系统综述,检索MEDLINE、Embase和Cochrane对照试验中心注册库,从建库至2023年6月6日。
- 纳入报告发病率、生存率或死亡率的基于人群的研究,共纳入来自24个国家的52项研究。
主要发现
- 诊断时最常见的分期为I期,最常见的部位为头颈部。
- MCC发病率随时间增加(高确定性),澳大利亚报告发病率最高(2.5/10万),新西兰为0.96/10万(高确定性)。
- 男性患者发病率通常高于女性患者(高确定性),但随时间有一些变化。
- 生存率较低和/或死亡率较高与男性性别(中等确定性)、诊断时分期较高(中至高确定性)、年龄较大(中等确定性)和免疫抑制(低至中等确定性)相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer that most commonly occurs in ultraviolet-exposed body sites. The epidemiology of MCC in different geographies and populations is not well characterized. OBJECTIVES: The objective of this systematic review is to summarize evidence on the incidence, mortality and survival rates of MCC from population-based studies. METHODS: We searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials from database inception to 6 June 2023. No geographic, age or date exclusions were applied. We included population-based studies of MCC that reported the incidence, survival or mortality rate, and also considered systematic reviews. A data-charting form was created and validated to identify variables to extract. Two reviewers then independently charted the data for each included study with patient characteristics, and estimates of incidence rate, mortality rate, and survival rate and assessed the quality of included studies using the Joanna Briggs Institute Checklist for Prevalence studies, Newcastle-Ottawa Scale and Assessment of Multiple Systematic Reviews. We abstracted age-, sex-, stage- and race-stratified outcomes, and synthesized comparisons between strata narratively and using vote counting. We assessed the certainty of evidence for those comparisons using the Grading of Recommendations, Assessments, Developments and Evaluations framework. RESULTS: We identified 11 472 citations, of which 52 studies from 24 countries met our inclusion criteria. Stage I and the head and neck were the most frequently reported stage and location at diagnosis. The incidence of MCC is increasing over time (high certainty), with the highest reported incidences reported in southern hemisphere countries [Australia (2.5 per 100 000); New Zealand (0.96 per 100 000) (high certainty)]. Male patients generally had higher incidence rates compared with female patients (high certainty), although there were some variations over time periods. Survival rates varied, with lower survival and/or higher mortality associated with male sex (moderate certainty), higher stage at diagnosis (moderate-to-high certainty), older age (moderate certainty), and immunosuppression (low-to-moderate certainty). CONCLUSIONS: MCC is increasing in incidence and may increase further given the ageing population of many countries. The prognosis of MCC is poor, particularly for male patients, those who are immunosuppressed, and patients diagnosed at higher stages or at an older age.
引用
- Mohsen ST, Price EL, Chan AW, et al. Incidence, mortality and survival of Merkel cell carcinoma: a systematic review of population-based studies. Br J Dermatol. 2024. PMID: 37874770. doi:10.1093/bjd/ljad404
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。